Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioDelivery Sciences International, Inc is a biotechnology business based in the US. BioDelivery Sciences International shares (BDSI) are listed on the NASDAQ and all prices are listed in US Dollars. BioDelivery Sciences International employs 176 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$3.04 - $5.45|
|50-day moving average||$3.63|
|200-day moving average||$3.93|
|Wall St. target price||$7.08|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing BioDelivery Sciences International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioDelivery Sciences International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioDelivery Sciences International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, BioDelivery Sciences International shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioDelivery Sciences International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.95. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioDelivery Sciences International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioDelivery Sciences International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $45.6 million.
The EBITDA is a measure of a BioDelivery Sciences International's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$156.5 million|
|Operating margin TTM||24.37%|
|Gross profit TTM||$131.8 million|
|Return on assets TTM||11.27%|
|Return on equity TTM||28.89%|
|Market capitalisation||$354 million|
TTM: trailing 12 months
There are currently 3.9 million BioDelivery Sciences International shares held short by investors – that's known as BioDelivery Sciences International's "short interest". This figure is 0.2% down from 3.9 million last month.
There are a few different ways that this level of interest in shorting BioDelivery Sciences International shares can be evaluated.
BioDelivery Sciences International's "short interest ratio" (SIR) is the quantity of BioDelivery Sciences International shares currently shorted divided by the average quantity of BioDelivery Sciences International shares traded daily (recently around 1.3 million). BioDelivery Sciences International's SIR currently stands at 2.98. In other words for every 100,000 BioDelivery Sciences International shares traded daily on the market, roughly 2980 shares are currently held short.
However BioDelivery Sciences International's short interest can also be evaluated against the total number of BioDelivery Sciences International shares, or, against the total number of tradable BioDelivery Sciences International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioDelivery Sciences International's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 BioDelivery Sciences International shares in existence, roughly 40 shares are currently held short) or 0.0426% of the tradable shares (for every 100,000 tradable BioDelivery Sciences International shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioDelivery Sciences International.
Find out more about how you can short BioDelivery Sciences International stock.
We're not expecting BioDelivery Sciences International to pay a dividend over the next 12 months.
Over the last 12 months, BioDelivery Sciences International's shares have ranged in value from as little as $3.04 up to $5.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioDelivery Sciences International's is 0.759. This would suggest that BioDelivery Sciences International's shares are less volatile than average (for this exchange).
BioDelivery Sciences International, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.